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A growing body of evidence suggests that autoreactive CD8 T cells contribute to the dis-
ease process in multiple sclerosis (MS). Lymphocytes in MS plaques are biased toward
the CD8 lineage, and MS patients harbor CD8T cells speciﬁc for multiple central nervous
system (CNS) antigens. Currently, there are relatively few experimental model systems
available to study these pathogenic CD8T cells in vivo. However, the few studies that have
been done characterizing the mechanisms used by CD8T cells to induce CNS autoimmu-
nity indicate that several of the paradigms of how CD4T cells mediate CNS autoimmunity
do not hold true for CD8T cells or for patients with MS.Thus, myelin-speciﬁc CD4T cells are
likely to be one of several important mechanisms that drive CNS disease in MS patients.
The focus of this review is to highlight the current models of pathogenic CNS-reactive
CD8 T cells and the molecular mechanisms these lymphocytes use when causing CNS
inﬂammation and damage. Understanding how CNS-reactive CD8T cells escape tolerance
induction and induce CNS autoimmunity is critical to our ability to propose and test new
therapies for MS.
Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, T cells, tolerance, autoimmunity,
central nervous system, MHC,TCR
MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is the most common neurological dis-
ease of young adults with over one million individuals worldwide
afﬂicted by the disease (Noseworthy et al., 2000; Haﬂer et al.,
2005; McFarland and Martin, 2007; Steinman, 2009). MS is an
inﬂammatory disease of the central nervous system (CNS) that
causes the demyelination of nerve cells and destroys oligoden-
drocytes, neurons, and axons (Lucchinetti et al., 2000; Frohman
et al., 2006; Dutta and Trapp, 2007). Traditionally it has been
thought that MS is an inﬂammatory disease primarily local-
ized to the white matter of the brain and spinal cord. However,
more recent studies have identiﬁed gray matter lesions in MS
patients that appear at the earliest stages, accumulate over time,
and exceed white matter lesions in progressive MS patients (Peter-
son et al., 2001; Bo et al., 2003; Calabrese et al., 2007; Lassmann
et al., 2007; Fisher et al., 2008; Ontaneda et al., 2011). Within
active MS lesions, the inﬂammatory immune cells are predom-
inantly T cells and activated macrophages and microglia, and
often form focal demyelinating plaques (Frohman et al., 2006;
Lassmann et al., 2007). The targeting of the CNS by immune
cells and the ensuing death of neuronal tissue causes a wide
spectrum of disease pathologies in MS patients (Noseworthy
et al., 2000; Keegan and Noseworthy, 2002; Haﬂer et al., 2005;
Frohman et al., 2006). The disease course can be progressive
with steadily increasing neurological deﬁcits, or manifest as a
relapsing–remitting disease, with discrete attacks of disease symp-
toms followed by periods of clinical stability (Steinman, 2009).
The clinical signs of MS are highly variable. MS patients often
have symptoms of upper motor neuron disease that include
hyperreﬂexia, ataxia, spasticity, and visual defects. In some cases
there is evidence of lower motor neuron disease such as sensory
defects and partial or complete paralysis (Keegan and Noseworthy,
2002).
It is hypothesized that MS is a T cell mediated autoimmune
disease. This hypothesis is primarily based on the genetic suscep-
tibility of individuals for the disease, the presence of immune cells
within active MS plaques and animal models of CNS autoimmu-
nity mediated by T cells (McFarland and Martin, 2007; Steinman,
2009). The genetic susceptibility for MS is polygenic; however, the
most prominent predisposing genetic element is genes within the
major histocompatibility complex (MHC) locus (Fogdell-Hahn
et al., 2000; Sospedra and Martin, 2005; Haﬂer et al., 2007; Ols-
son and Hillert, 2008; Sawcer et al., 2011). The MHC locus is a
large gene cluster consisting of over 200 expressed genes. Due to
extensive linkage disequilibrium it has been difﬁcult to parse out
the precise predisposing genes. In MS, it is now clear that the
HLA-DR15 and HLA-DQ6 alleles of MHC class II have strong
disease susceptibility association with MS (Haﬂer et al., 2007;
Olsson and Hillert, 2008; Sawcer et al., 2011). These particular
MHC alleles may be displaying particular sets of peptide anti-
gens to autoreactive T cells (Wucherpfennig, 2001). In addition
to MHC genes, polymorphisms in multiple immunologically rel-
evant genes, including IL-7R and IL-2R, have been associated with
MS susceptibility (Haﬂer et al., 2007; Sawcer et al., 2011). There-
fore, one hypothesis has been that predisposing MHC class II
alleles present particular disease relevant epitopes to dysregulated,
pathogenic T cells. However, other MHC class II alleles can con-
fer some protection from disease even when the susceptible MHC
class II allele is expressed (Olsson and Hillert, 2008; Ramagopalan
et al., 2009). This suggests that the role of MHC in autoimmunity is
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likely to be multi-layered, involving functions from multiple gene
products.
CD4 T cells speciﬁc for many CNS proteins, including myelin
associated glycoprotein (MAG), myelin basic protein (MBP),
myelin oligodendrocyte glycoprotein (MOG), and proteolipid
protein (PLP), can be isolated from MS patients and healthy indi-
viduals (Sospedra and Martin, 2005). These data, combined with
evidence that MHC class II alleles confer the strongest genetic
susceptibility,has suggested that in patientswithMS,CNSprotein-
speciﬁc CD4 T cells become activated, cross the blood/brain bar-
rier, and induce CNS autoimmunity (Sospedra and Martin, 2005;
Steinman, 2009). Further support for this hypothesis comes from
the many animal models of CD4 T cell mediated experimental
autoimmune encephalomyelitis (EAE), that manifest clinical and
pathological symptoms with many similarities to MS (Kuchroo
et al., 2002; Ercolini and Miller, 2006; Goverman, 2009).
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
Animal models of CNS autoimmunity are primarily focused on
the role of Th1 and Th17 phenotype CD4 T cell mediated pathol-
ogy (Bettelli et al., 2007; Goverman, 2009). The majority of CNS
proteins identiﬁed that can be targets of EAE-inducing CD4 T
cells are components of compact myelin or proteins associated
with myelin synthesis (Sospedra and Martin, 2005). The classical
animal model of MS, CD4 T cell mediated EAE (CD4–EAE), is
induced by immunizing animals with myelin proteins or peptides
emulsiﬁed in complete Freund’s adjuvant. This protocol predom-
inantly induces Th1 and Th17 phenotype CD4 T cell responses,
and is a poor elicitor of CD8 responses (Zamvil and Steinman,
1990; Cua et al., 2003). In addition, CD4–EAE is induced by trans-
ferring CNS-speciﬁc Th1 or Th17 CD4 T cells into naïve recipient
animals (Zamvil and Steinman, 1990; Langrish et al., 2005; Lees
et al., 2008; O’Connor et al., 2008; Jager et al., 2009). Similar to
patients with MS, the disease course of CD4–EAE can be acute,
relapsing/remitting, or chronic progressive. However, the disease
pathologies associated with CD4–EAE are usually less diverse than
the disease symptoms in MS patients (Steinman and Zamvil, 2005;
Friese et al., 2006; Gold et al., 2006).
The major mouse models of EAE–MOG induced EAE in
C57BL/6 mice, MBP induced EAE in B10.PL mice, and PLP medi-
ated disease in SJL mice – present symptoms of ascending ﬂaccid
paralysis (Zamvil and Steinman, 1990; Vanderlugt and Miller,
2002). The disease begins with a loss of tail tone and can progress
through an ascending paralysis affecting the rear legs, followed by
the fore legs until the animals become morbid. These pathologies
are reminiscent of MS patients with lower motor neuron disease
(Keegan and Noseworthy, 2002). There are some models of CD4–
EAE that present “atypical” axial-rotatory disease, characterized
by mice that roll continuously or have severe deﬁciency in balance
without paralysis (Greer et al., 1996; Sobel, 2000; Abromson-
Leeman et al., 2007; Lees et al., 2008; Stromnes et al., 2008). Several
studies have shown that the ratio of Th1 versus Th17, or the ability
of CNS cells to respond to IFNγ signaling, contributes to the loca-
tion of affected CNS area and/or the presentation of classical or
atypical disease symptoms (Lees et al., 2008; Stromnes et al., 2008;
Jager et al., 2009). The genetic background of mice that get CD4
T cell mediated atypical EAE include C57BL/6, Balb/c, and C3H
mice, genetic backgrounds that also develop classical ascending
paralytic disease when immunized with different CNS antigens
(Sobel, 2000). Thus, there are indications that the immunizing
antigen, T cell trafﬁcking and/or the phenotype of the CD4 T cells,
and not necessarily the genetic background, may be determin-
ing factors in the induction of non-classical disease symptoms of
EAE. Overall, although there are heterogenic disease pathologies
induced by CD4 T cells, CD4–EAE still likely mimics some, but
not all, aspects of CNS inﬂammation in MS.
Autoreactive CD4 T cells alone are unlikely to fully account
for all of the effector mechanisms that drive the disease process
in MS. Disease inducing, myelin-speciﬁc CD4 T cells within the
CNS release the signature Th1 and Th17 cytokines. The release of
cytokines and chemokines causes an increase in MHC expression
within the CNS, leads to the activation of microglia, and induces
the recruitment of monocytes and non-speciﬁc T cells to the area
of inﬂammation (Prineas, 1979; Raine et al., 1984; Carson et al.,
1999; Brabb et al., 2000; Krakowski and Owens, 2000; Juedes and
Ruddle, 2001; Becher et al., 2006; Mildner et al., 2008). Several
of these cytokines, including IFNγ, TNFα, IL-6, IL-12, and IL-23,
have been directly implicated in disease pathogenesis (Krakowski
and Owens, 1996; Okuda et al., 1998; Sean Riminton et al., 1998;
Steinman, 2001;Cua et al., 2003;Deshpande et al., 2006). Using the
CD4–EAE disease model as a screen, several therapies that ame-
liorate CD4–EAE have been developed for clinical trials to reduce
symptoms in MS patients. While some of the treatments validated
in the CD4–EAE model have reduced disease symptoms in MS
patients, other therapies have not affected clinical symptoms, or
have been detrimental to patients (Steinman and Zamvil, 2005;
Friese et al., 2006; Gold et al., 2006). For example, the removal of
CD4 T cells or TNFα from MS patients had little effect on disease
symptoms, while both abolish disease in CD4–EAE models (Wal-
dor et al., 1985; Llewellyn-Smith et al., 1997; van Oosten et al.,
1997; Sean Riminton et al., 1998; Lenercept, 1999). Thus, CD4–
EAE probably mimics only a subset of the events that occur during
MS. The discovery of other key events in the pathogenesis of MS
disease will be facilitated by animal models that mimic events not
already evoked by CD4 T cells.
CD8 T CELLS IN MULTIPLE SCLEROSIS
The lymphocytes inMSplaques are biased toward theCD8 lineage.
This bias occurs regardless of the stage of activity or disease, and
can be as prominent as 10:1, CD8 versus CD4 T cells (Booss et al.,
1983; Traugott et al., 1983b; Hauser et al., 1986; Babbe et al., 2000;
Lassmann et al., 2007). At the margin of chronic and active lesions,
CD8 T cells have been identiﬁed interacting with antigen present-
ing cells (APC; Seraﬁni et al., 2006). Through normally poorly
expressed, MHC class I proteins are highly expressed within the
MS lesion on astrocytes, oligodendrocytes, and neurons, imply-
ing that CD8 T cells could be directly engaging these cell types as
well (Traugott et al., 1983a; Wong et al., 1984a; Neumann et al.,
1995, 1997). CD8 T cells with an activated/memory phenotype
have been observed to be enriched within the CNS tissue and
cerebrospinal ﬂuid (CSF) of MS patients (Jacobsen et al., 2002;
Junker et al., 2007), and histological analysis of some cases of
acute MS have shown granzyme B-expressing CD8 T cells in close
proximity or attached to oligodendrocytes or demyelinated axons
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(Neumann et al., 2002; Seraﬁni et al., 2006; Lassmann et al., 2007).
Interestingly, Fugger and colleagues have found that a large per-
centage of CD8 T cells in acute and chronic MS lesions express
IL-17 (Tzartos et al., 2008), a highly pro-inﬂammatory cytokine
associated with pathogenic Th17 CD4 T cells and Tc17 CD8 T
cells (Cua et al., 2003; Bettelli et al., 2007). This activated/memory
phenotypic skewing of CD8 T cells within the CSF occurs even in
early diagnosed MS patients. Furthermore, Brück and colleagues
demonstrated that the number of CD8 T cells and macrophages
within the lesions correlates with the extent of acute axonal dam-
age, as deﬁned by the accumulation of amyloid precursor protein
(APP; Bitsch et al., 2000). In addition, genetic association studies
have identiﬁed some MHC class I alleles, including HLA-A3, as a
genetic susceptibility allele (Friese and Fugger, 2005; Sawcer et al.,
2011). In contrast, the MHC class I allele, HLA-A∗0201, has been
shown to reduce the risk of MS in individuals that express the
MHC class II proteins, HLA-DRB1∗1501, and DQB1∗06 (Fogdell-
Hahn et al., 2000; Brynedal et al., 2007). These observations sup-
port the idea that CD8 T cells are involved in pathogenesis of MS,
as active contributors to the development of MS lesions, and/or as
protective regulatory T cell populations that limit disease.
Several groups have isolated T cells from the blood, CSF, and
MS lesions (via microdissection), and analyzed these lymphocytes
by complementarity determining region 3 (CDR3) spectratyping
to determine the diversity of T cell clones. Initial studies by Babbe
et al. (2000) demonstrated that the majority of CD8 T cells within
an MS plaque were progeny of a few initial clones. One particular
clone accounted for 35% of the CD8 T cells within an MS plaque.
Later studies analyzing larger numbers of MS patients demon-
strated that CD8 T cells isolated from CSF ﬂuid also contained
clonal expansions, some of which persisted for 5 years (Jacobsen
et al., 2002; Skulina et al., 2004). To identify the antigen speciﬁcity
of these CD8 T cells, paired TCRα, and TCRβ chains have been
cloned and re-expressed in T cell lines (Seitz et al., 2006). However,
the antigen speciﬁcity of these CD8 T cells has yet to be deter-
mined. Although the speciﬁcity of the CD8 T cells in MS plaques
is unknown, their clonal nature suggests that they are responding
against selected antigens.
Central nervous system-reactive CD8T cellsmay be pathogenic
in MS patients. Pioneering studies by Biddison and colleagues and
Haﬂer and colleagues identiﬁed and analyzed CD8 T cells speciﬁc
for several CNS proteins, including MAG, MBP, and PLP, from
MS patients (Tsuchida et al., 1994; Dressel et al., 1997). These
studies clearly demonstrated that MS patients carry a population
of CD8 T cells speciﬁc for myelin proteins. These MAG-, MBP-,
and PLP-speciﬁc CD8 T cells are capable of killing neuronal cells
in vitro and release TNFα and IFNγ, suggesting that they may con-
tribute to CNS disease, although the precise role of these cells in
the pathogenesis of MS has not been fully elucidated (Tsuchida
et al., 1994; Jurewicz et al., 1998; Medana et al., 2001). More recent
analysis of peripheral blood suggests that MS patients carry CD8
T cells able to express IFNγ and TNFα in response to a multi-
tude of CNS protein epitopes. Several studies have demonstrated
that these CNS-reactive CD8 T cells were found in greater fre-
quency and bore an activated/memory phenotype in MS patients,
suggesting they had been activated within the patient by CNS anti-
gens (Crawford et al., 2004; Zang et al., 2004; Niland et al., 2005).
In contrast, these same T cells isolated from control subjects dis-
played a naïve T cell phenotype. Differences in the frequency of
CNS antigen-speciﬁcCD8T cells betweenMSpatients and control
subjects have not always been observed, as myelin-reactive CD8 T
cells have been identiﬁed in healthy subjects as well (Berthelot
et al., 2008). This group of studies clearly indicates that individ-
uals carry a population of CD8 T cells speciﬁc for a variety of
CNS antigens. The presence of CNS-reactive T cells exhibiting an
activated/memory phenotype in MS patients and the oligoclonal
nature of CD8 T cells within MS plaques suggest that CD8 T
cells are active participants within the destructive CNS immune
response.
In addition to a pathogenic role for CD8 T cells in MS, regu-
latory CD8 T cells may contribute to limiting disease severity or
occurrence in MS patients. Early experiments demonstrated that
the suppressor function of CD8 T regulatory cells in MS patients
may be defective as compared to healthy individuals (Antel et al.,
1986). Consistent with these ﬁndings, a speciﬁc CD8 T cell clone
has been shown to regulate MBP-speciﬁc CD4 T cells (Chou et al.,
1992). CD8 T cells that can lyse myelin-speciﬁc CD4 T cells have
been detected in MS patients, and vaccination of MS patients with
irradiated myelin-speciﬁc CD4 T cells elicited CD8 T cells that
could speciﬁcally kill theseCD4Tcells (Zhang et al., 1993;Correale
et al., 2000).More recently, longitudinalmagnetic resonance imag-
ing (MRI) analysis has shown a negative correlation between the
percentage of Tc2 cytokine-producing CD8 T cells in the periph-
ery of MS patients and the development of lesions (Killestein et al.,
2003). Furthermore, the beneﬁcial effects of treating MS patients
with glatiramer acetate may in part be due to activating regula-
tory CD8 T cells (Tennakoon et al., 2006). In addition to these,
and many other studies of human CD8 T regulatory cells, mouse
models have also shown potent disease modifying effects of CD8
T regulatory cells through the secretion of IL-10 and other soluble
mediators, the regulation of APC function, as well as by elimi-
nating activated CD4 T cells by CD8 T cells via recognition of
the non-classical Qa-1 MHC molecule (Jiang and Chess, 2006;
Goverman, 2009).
ANIMAL MODELS OF CD8 T CELL MEDIATED CNS
AUTOIMMUNITY
Several years agowe andothers starteddevelopingCD8Tcellmod-
els of CNSautoimmunity.At the time,MSwas generally believed to
be primarily aCD4T cellmediated autoimmune disease.However,
because MS plaques contain a large excess of CD8 T cells relative
to CD4 T cells, we were concerned that a major lymphocyte pop-
ulation within the inﬂamed site was being under studied. Because
of the cytotoxic and pro-inﬂammatory nature of CD8 T cells, we
hypothesized that myelin-speciﬁc CD8 T cells contribute to CNS
autoimmunity.Our studies focused onwhetherMBP-speciﬁcCD8
T cells could induce CNS autoimmunity. Because MBP is a self
protein, we were concerned that CD8 T cells speciﬁc for MBP
might be subject to immune tolerance mechanisms. To avoid
tolerance issues, we initially isolated MBP-reactive CD8 T cells
from C3H MBP-deﬁcient shiverer (C3H MBP−/−) mice (Huseby
et al., 1999). These studies demonstrated that MBP-speciﬁc CD8
T cells, similar to several CD4 T cell epitopes of MBP and PLP, are
subject to immune tolerance (Goverman, 2011). However, some
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MBP-speciﬁc CD8 T cells are present in the peripheral repertoire
of wild-type C3H mice. Furthermore, the activation of MBP-
speciﬁc CD8 T cells in animals induces severe, demyelinating CNS
autoimmunity (Huseby et al., 2001a).
The pathology of MBP-speciﬁc CD8 T cell mediated disease
had many similarities to some human MS patients (Lucchinetti
et al., 2000), including the presence of lesions throughout the brain
(Huseby et al., 2001a). Histological analysis of diseased brains
indicated the lesions were vascular in nature, involving capillar-
ies and venules, and consisted of perivascular cufﬁng. Vacuolation
of the surrounding nervous tissue was common and consisted
of demyelination and cytoplasmic swelling. In contrast to many
typical CD4–EAE models, this MBP-speciﬁc CD8 T cell medi-
ated disease model had a predominance of lesions in the brain
instead of the spinal cord, displayed a general lack of inﬂam-
mation (except that which was directly associated with vascular
walls), and showed severe demyelination and perivascular cell
death, suggesting a cytotoxic or ischemic injury. Antibody block-
ing experiments demonstrated a role for IFNγ in contributing
to disease severity (Huseby et al., 2001a). Using TCR Tg mice
that generate MBP-speciﬁc CD8 T cells, Goverman and colleagues
have gone on to show how endogenous MBP inﬂuences this T cell
repertoire (Perchellet et al., 2004, 2008), and have demonstrated
that viruses can induce CD8 T cell-mediated autoimmunity by
breaking peripheral tolerance mechanisms (Ji et al., 2010).
CD8 T cell lines reactive to the MOG derived peptide,
MOG35–55, can induce chronic CNS autoimmunity in C57BL/6
mice (Sun et al., 2001; Ford and Evavold, 2005). Unlike the disease
symptoms induced by MBP-speciﬁc CD8 T cells, these MOG-
reactive CD8 T cell lines induced ascending ﬂaccid paralysis, and
caused lesions in both the spinal cord and brain. The reason for
the differences in disease symptoms between the MBP and MOG
models of CD8–EAE is unknown. The differences could be due to
the CD8 T cells targeting different proteins or due to differences
between the C3H and C57BL/6 genetic backgrounds.
Humanized mouse models have been used to study CD8 T cell
responses targeting myelin epitopes presented by human HLA-A
molecules. CD8 T cells targeting MOG181–189, presented by the
MHC class I allele, HLA-A∗0201, were observed to potentiate an
autoreactive CD4 T cell response by accelerating and worsening
the encephalitogenic process (Mars et al., 2007). Friese et al. (2008)
have more recently generated a humanized mouse model of MS in
which an MHC class I-restricted TCR speciﬁc for PLP45–53 bound
to HLA-A∗0301, isolated from an MS patient, is expressed in mice
which also express the MHC Class I molecule HLA-A∗0301. These
mice, constructed on aC57BL/6 genetic background,develop a low
grade spontaneous MS-like disease which becomes more severe
upon immunization with PLP peptides. Following immunization
with PLP peptides, there are two phases of disease, an early inﬁltra-
tion that is dominated by CD8 T cells and late disease that requires
MHC class II expression. Coincident with the late disease is the
expansion within the CNS of CD4 T cells reactive to MOG35–55.
These experiments nicely demonstrate that T cells expressing a
human MHC class I-restricted TCR speciﬁc for a CNS protein can
be pathogenic and can induce epitope spreading to the CD4 T
cell compartment. When the human TCR Tg mice were crossed
onto mice expressing HLA-A 0301 and the protective MHC class I
allele, HLA-A∗0201, thymocytes expressing this PLP-speciﬁc TCR
were subject to elimination by negative selection. T cells expressing
the PLP45–53-speciﬁc TCR did not recognize the PLP45–53 epitope
bound to HLA-A∗0201, suggesting the elimination of these path-
ogenic T cells was not induced by recognizing endogenous PLP
(Friese et al., 2008). The induction of negative selection in mice
expressing HLA-A∗0201 support the hypothesis that one of the
protective effects of speciﬁc MHC class I alleles is the elimination
of pathogenic T cells during development.
Complementing the active induction models are a set of mice
which spontaneously succumb to CD8 T cell-dependent CNS
autoimmunity. Fournier and colleagues observed that transgenic
C57BL/6 mice, in which the co-stimulatory molecule CD86 is
constitutively expressed on peripheral T cells and resident CNS
microglia, succumb to a CD8 T cell-dependent CNS demyelinat-
ing disease (Brisebois et al., 2006). CNS inﬁltration by CD8 T cells
results in mice which display a deterioration of hind-limb control
and coordination, weak tail movement, and weight loss. The age
at which these mice succumb to spontaneous disease is younger in
both MHC class II-deﬁcient mice as well as CD4-deﬁcient mice,
suggesting the pathogenic CD8 T cells are being regulated by a
CD4 T cell populations. The speciﬁcity of these pathogenic CD8
T cells has yet to be determined. The non-paralytic disease symp-
toms and pathologies in CD86 transgenic mice are similar to the
MBP-speciﬁc CD8 T disease model in C3H mice, while differing
from the paralytic disease mediated by MOG35–55 speciﬁc CD8 T
cells. Two additional models have recently been observed in which
pathogenic CD8 T cells induce both clinical signs of CNS dis-
ease as well as demyelination. Mice over-expressing PLP within
oligodendrocytes of the CNS developed progressive clinical signs
of neurological damage including ataxia, tremors, and seizures
after 12–18months of age that was dependent up CD8 T cells (Ip
et al., 2006). CD8 T cells and macrophages accumulated within the
brains of these mice, with a limited B cell and CD4 T cell compo-
nent. Affected areas of the CNS included the optic nerve, cerebral
white matter, and spinal cord. Mice in which the oligodendrocytes
are deﬁcient in peroxisome show a similar axonal loss and neu-
roinﬂammation as the PLP over-expressing mice (Kassmann et al.,
2007). The antigen speciﬁcity of the CNS inﬁltrating CD8 T cells
remains unknown in both models. These spontaneous models,
along with the active induction models, further suggest that CD8
T cells can induce a range of different disease manifestations, and
clearly demonstrate that CNS-speciﬁc CD8 T cells are present in
the peripheral T cell repertoire and when activated, can induce
CNS autoimmunity.
CELLULAR TARGETS OF PATHOGENIC CD8 T CELLS
The cellular target of pathogenic myelin-speciﬁc CD8 T cells
in vivo is unknown. Normally, there is very little MHC class I
expression in theCNS.Neurons andoligodendrocytes express only
low levels of MHC class I, constitutively. Astrocytes, microglia,
blood vessel endothelial cells, and bone marrow derived-APC
(BM-APC) resident within the CNS do express MHC class I con-
stitutively, though none of these cells synthesize myelin antigens
(Traugott et al., 1983a; Wong et al., 1984a; Massa et al., 1993; Neu-
mann et al., 1995, 1997; Hoftberger et al., 2004; Frohman et al.,
2006). However, BM-APC, and to a lesser extent, blood vessel
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endothelial cells, can cross-present exogenously synthesized pro-
teins on MHC class I proteins (Limmer et al., 2000; Rock and Shen,
2005; Galea et al., 2007). Thus, the initial recognition of myelin
peptides presented on MHC class I proteins is likely by BM-APC
or blood vessel endothelial cells. Whether CD8 T cells can directly
lyse oligodendrocytes in vivo is unknown. MHC expression by
oligodendrocytes does increase after inﬂammation or in response
to IFNγ, therefore it may be possible for CD8 T cells to directly
target oligodendrocytes once inﬂammation begins (Wong et al.,
1984a,b; Tsuchida et al., 1994; Neumann et al., 1997; Hoftberger
et al., 2004). Thus, it is not surprising that when we and others
neutralized IFNγ, the severity of CD8–EAE disease is drastically
reduced (Huseby et al., 2001a; Brisebois et al., 2006).
To begin to identify which CNS cell types could be targets of
CD8 T cells, several groups have created transgenic mice which
express neo-self antigens in speciﬁc cell populations. The ﬁrst of
these models, created by the Oldstone group, expressed the lym-
phocytic choriomeningitis virus (LCMV) glycoprotein under the
MBP promoter (Evans et al., 1996). These mice expressed very
low levels of the LCMV protein exclusively in the brain, likely in
oligodendrocytes. Following two subsequent viral infections, focal
areas of myelin degradation were observed, and expression of both
MHCclass I and class IImoleculeswas foundonoligodendrocytes.
These data suggested that CD8 and/or CD4 T cells may interact
directly with oligodendrocytes and play a role in oligodendrocyte
injury. More recently, two sets of mice expressing either ovalbu-
min (OVA) or the inﬂuenza virus hemagglutinin (HA) proteins
selectively within oligodendrocytes, have been constructed and
analyzed.
When mice expressing OVA selectively in oligodendrocytes
(ODC–OVA) were genetically crossed with OT-1 mice, transgenic
mice expressing aTCRspeciﬁc forOVA257–264 presentedbyH2-Kb,
the double transgenic mice succumbed to an extremely aggres-
sive, lethal fulminant demyelinating CNS autoimmunity (Na et al.,
2008). Lesions within the cerebellum, brainstem, optic nerve, and
spinal cord were observed. In vitro, OVA-transgenic oligodendro-
cytes were capable of activating naïve OT-I cells. The potency of
OVA-expressing oligodendrocytes to activate OT-I CD8 T cells
in vitro was further ampliﬁed by the addition of exogenous IFNγ
to the cultures. The secretion of IFNγ from OT-1 T cells was also
found to be required for the loss of oligodendrocytes, as well as
axon damage within the CNS. In contrast to this model, Balb/c
mice expressing the HA protein in oligodendrocytes (MOG–HA)
did not develop spontaneous autoimmunity when crossed with
transgenic mice expressing an HA-speciﬁc TCR, Cl4, that rec-
ognizes HA512–520 presented by H2-Kd (Saxena et al., 2008). In
these mice, the HA-speciﬁc CD8 T cells maintained ignorance
to the neo-self protein. However, transfer of in vitro activated
HA-speciﬁc CD8 T cells induced weight loss, demyelination, and
reduced mobility, but not paralysis. The inﬂammatory lesions
were primarily within the spinal cord and optic nerve. HA-speciﬁc
CD8 T cells within the CNS were found in close apposition with
oligodendrocytes and some had polarized Granzyme B contain-
ing granules toward the oligodendrocytes (Saxena et al., 2008).
The loss of oligodendrocytes prior to demyelination suggests these
CD8 T cells are directly killing these cells. Interestingly, when these
same HA-speciﬁc CD8 T cells are transferred into mice expressing
the HA protein selectively in astrocytes, the mice developed a
monophasic brain inﬂammation with an absence of any clinical
signs of disease (Cabarrocas et al., 2003). Combined, these data
suggest that CD8 T cells, which have a strong reactivity for an
epitope that is processed and presented well on MHC class I mol-
ecules, can directly target oligodendrocytes within the CNS. The
differences in disease course and severity among the transgenic
neo-self models of CD8 T cell mediated CNS autoimmunity fur-
ther suggests that a multitude of factors, including target antigen
expression level, CNS cell type expression, TCR–pMHC afﬁnity,
and genetics, likely contribute to whether a CD8 T cell response is
pathogenic.
WHY ARE PATHOGENIC CNS-REACTIVE CD8 T CELLS
PRESENT WITHIN THE MATURE T CELL REPERTOIRE?
The T cell mediated autoimmune nature of MS and EAE indi-
cates that T cell tolerance of CNS proteins is incomplete. During
T cell development, TCR undergo somatic recombination of their
peptide and MHC binding CDR3 loops, as well as TCRα/β chain
pairing (Davis and Bjorkman, 1988). The immense TCR diversity
generated during T cell development allows the adaptive immune
response tobe able to generate speciﬁcT cell responses tounknown
pathogens. This process, however, also creates self-reactive T cells.
Many of these self-reactive T cells are purged during negative selec-
tion, due to the expression of the self protein within the thymus by
dendritic cells or medullary thymic epithelial cells (Kappler et al.,
1987; Kisielow et al., 1988; Mathis and Benoist, 2004; Kyewski and
Klein, 2006). However, some self-reactive T cells that escape nega-
tive selection are then subject to peripheral tolerance mechanisms
(Zheng and Rudensky, 2007). Autoimmune diseases arise when
failures of thymic and peripheral tolerance mechanisms allow self-
reactive T cells to be activated and attack healthy tissues. It has been
clearly established that endogenous MBP induces some tolerance
to the CD4 and CD8 T cell repertoire (Goverman, 2011). PLP
also appears to induce some tolerance to the CD4 T cell repertoire
speciﬁc for it (Kuchroo et al., 2002). Because MBP and PLP are
expressed at extremely high levels within the CNS and some iso-
forms of these proteins are expressed within the thymus (albeit
at extremely low levels by medullary thymic epithelial cells), it is
not surprising some T cell tolerance occurs (Kyewski and Klein,
2006). Negative selection can also occur to T cells speciﬁc for CNS
proteins not expressed in the thymus. Our studies of CD4 T cells
speciﬁc for MBP121–140, an epitope that is not expressed in the
thymus, indicate that BM-APC can acquire MBP from exogenous
sources and cause the elimination of developing T cells (Huseby
et al., 2001b). The extremely low level of MOG (around 1,000–
5,000 times less abundant than MBP and PLP within the CNS)
does not appear to induce signiﬁcant tolerance to the CD4 T cell
repertoire (Delarasse et al., 2003). It has not been determined
whether other myelin proteins induce CD4 T cell tolerance, nor is
it known whether CNS proteins other than MBP induce tolerance
to the CD8 T cell repertoire.
There are three main hypotheses for how pathogenic myelin-
reactive T cells escape tolerance induction in the thymus,primarily
derived from studies of CD4T cell responses: (1) T cells speciﬁc for
exons of myelin proteins neither expressed nor presented within
the thymus fail to be deleted because the antigen is not presented to
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developing thymocytes (Kuchroo et al., 2002; Kyewski and Klein,
2006). (2) For myelin proteins that are presented well in the thy-
mus, central tolerance eliminates thymocytes expressing TCR that
have a strong reactivity for these myelin antigens while allow-
ing thymocytes expressing TCR which have a weak reactivity to
develop (Goverman, 2011). Thymocytes that escape this form of
central tolerance may express TCR with a low afﬁnity for myelin
epitopes bound to self-MHC proteins, or express TCR that bind
myelin epitopes bound to self-MHC with unconventional binding
modes (Wucherpfennig et al., 2009). (3) Autoreactive T cells spe-
ciﬁc for myelin proteins that are expressed in the thymus but are
poorly presented (e.g., peptide sequences that bind MHC proteins
poorly)maynot be deleted because the amount of MHC + peptide
complex in the thymus is very low (Goverman et al., 1993; Liu
et al., 1995). Myelin-speciﬁc T cells expressing low afﬁnity TCR,
TCR that bind pMHC with unconventional bind modes, or TCR
that target epitopes that are poorly presented may be pathogenic
because the expression level of the myelin protein is much higher
in theCNS than thymus, and thusAPCwithin theCNS can present
enough MHC+ peptide complexes to activate these lymphocytes.
Do these models of T cell tolerance to myelin antigens hold
true for CD8 T cells as well? Though little is currently known
about how CNS-reactive CD8 T cells escape tolerance induction,
it was very surprising that some CD8 T cells with a strong reac-
tivity for MBP79–87 were allowed to develop and seed the mature
T cell repertoire (Huseby et al., 2001a). This myelin epitope is
expressed within the thymus and most T cells with a strong reac-
tivity for this epitope are eliminated. Using a completely novel
mechanism to escape tolerance induction, Perchellet et al. (2004)
found that MBP79–87-speciﬁc CD8 T cells could avoid both central
and peripheral deletion by removing H2Kk–MBP79-87 complexes
fromAPC without proliferating. Thus, the major form of immune
regulation that governs myelin-speciﬁc CD4 T cells may not fully
explain the development and control of CNS-reactive CD8 T cells.
To understand why CNS autoimmunity arises, it will be important
to identify the pathways in which CNS-reactive CD4 and CD8 T
cells are normally eliminated or regulated, and why these processes
fail in patients with MS. Overall, how similar or different the con-
tribution of CNS-reactive CD4 versus CD8 T cells to the disease
pathologies of MS is just beginning to be understood.
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